In the Spotlight...
Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected CAR-NKT cells
Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancer
Tumour-reactive heterotypic CD8 T cell clusters from clinical samples
EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors
Previous Digests
MiTEs turn TAM suppression into T cell synergy
November 26, 2025
Inhibition or reprogramming of tumor-associated macrophages (TAMs) has great potential to improve the tumor immune environment, but has, so far, shown limited clinical efficacy. To improve macrophage-targeted therapies, von Locquenghien, Zwicky, Cie, et al. described their dual TAM- and...
SITC - 40th Anniversary Annual Meeting 2025
November 19, 2025
The ACIR team attended the SITC - 40th Anniversary Annual Meeting 2025 in National Harbor, Maryland. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. Keynote addressJennifer A. Wargo...
N17350: a cytotoxic cancer therapy that spares the immune system
November 12, 2025
Cytotoxic cancer treatments, like chemotherapy and radiation, have the potential to synergize with immunotherapies through direct killing of tumor cells, which leads to the release of antigens and damage-associated molecular patterns. However, this potential synergy is often hindered when...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaelle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
